Background:
Alzheimer's disease (AD) is the leading cause of
dementia, resulting in impairments in
memory,
cognition,
decision-making, and
social skills. Thus, accurate preclinical
diagnosis of
Alzheimer's disease is paramount. The identification of
biomarkers for
Alzheimer's disease through
magnetic resonance spectroscopy (MRS) represents a novel adjunctive diagnostic approach.
Objective:
This study conducted a
meta-analysis of the diagnostic results of this
technology to explore its feasibility and accuracy.
Methods:
PubMed, Cochrane
Library, EMBASE, and Web of
Science databases were searched without restrictions, with the search period extending up to July 31, 2022. The search strategy employed a combination of
subject headings and
keywords. All retrieved
documents underwent
screening by two
researchers,
who selected them for
meta-analysis. The included
literature was analyzed using
Review Manager 5.4
software, with corresponding
bias maps,
forest plots, and summary
receiver operating characteristic (SROC) curves generated and analyzed.
Results:
A total of 344 articles were retrieved initially, with 11 articles meeting the criteria for inclusion in the
analysis. The
analysis encompassed data from approximately 1766
patients. In the
forest plot, both
sensitivity (95% CI) and
specificity (95% CI) approached 1. Examining the true positive rate, false positive rate, true negative rate, and false negative rate, all studies on the summary
receiver operating characteristic (SROC) curve clustered in the upper left quadrant, suggesting a very high accuracy of
biomarkers detected by MRS for diagnosing
Alzheimer's disease.
Conclusion:
The
detection of
biomarkers by MRS demonstrates feasibility and high accuracy in diagnosing AD. This
technology holds promise for widespread
adoption in the
clinical diagnosis of AD in the
future. (AU)